Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The effect of treatment withCorynebacterium parvum on the development and growth of experimental hematogenic metastases of schwannoma in the rat


Single i.v. administration ofCorynebacterium parvum 5 days before i.v. injection of 106 tissue cultured syngeneic schwannoma cells in Lewis rats resulted in extension of survival time (P<0.05). There was a significant decrease in metastatic tumor incidence for lung, heart, and kidney and decreased lung tumor growth with approximately 50% of the lung tumor burden of untreated controls (P<0.05). Rats treated similarly withC. parvum 10 days after tumor cell injection showed no enhanced survival; to the contrary, their survival was shortened. Moreover, tumor incidence in the post-treated group was not significantly different from the control but significantly increased in comparison to the pretreated group. Enhanced lung tumor growth resulted in a final tumor burden about twice that of untreated controls (P<0.05).

This is a preview of subscription content, log in to check access.


  1. 1.

    Bash JA (1978) Suppression of rat T-cell proliferation byCorynebacterium parvum: T-cell requirement for induction. J Reticuloendothel Soc 23:63–73

  2. 2.

    Bomford R (1977) An analysis of the factors allowing promotion (rather than inhibition) of tumour growth byCorynebacterium parvum. Int J Cancer 19:673–679

  3. 3.

    Cravioto HM, De Bernardo E, Hochwald GM, Thorbecke JG (1981) Immunity to transplantable nitrosourea-induced neurogenic tumors. I. Potentiation to tumor immunity withCorynebacterium parvum. J Neuropathol Exp Neurol 40: 526–536

  4. 4.

    Cruse JP, Lewis MR, Clark CG (1978)Corynebacterium parvum enhances colonic cancer in dimethylhydrazinetreated rats. Br J Cancer 37:639–643

  5. 5.

    Fisher RA (1958) Statistical methods for research workers, 13th edn. Hafner, New York, pp 96–97

  6. 6.

    Halpern B (1974)Corynebacterium parvum: Applications in experimental and clinical oncology. Proceedings of the First International Conference on the Effects ofCorynebacterium parvum in Experimental and Clinical Oncology, Paris, May 9–10. Plenum Press, New York

  7. 7.

    Israel L, Edelstein R, Depierre A, Dimitrov N (1975) Brief communication: Daily intravenous infusions ofCorynebacterium parvum in 20 patients with disseminated cancer: A preliminary report of clinical and biologic findings. J Natl Cancer Inst 55:29–33

  8. 8.

    Keuls M (1952) The use of the “studientized range” in connection with an analysis of variance. Euphytica 1:112–122

  9. 9.

    Kirchner H, Holden HT, Herberman RB (1975) Splenic suppressor macrophages induced in mice by injection ofCorynebacterium parvum. J Immunol 115:1212–1216

  10. 10.

    Koestner A (1973) Transplacental carcinogenesis. In: Scholefield PT (ed) Proceedings of the 10th Canadian Cancer Research Conference. University of Toronto Press, Toronto, pp 65–82

  11. 11.

    Mandybur TI, Brunner GD (1982) Experimental hematogenic metastases of malignant schwannoma in the rat. Acta Neuropathol (Berl) 57:151–157

  12. 12.

    Newman D (1939) The distribution range in samples from a normal population, expressed in terms of an independent estimate of standard deviation. Biometrika 31:20–30

  13. 13.

    Ojo E, Haller O, Kimura A, Wigzell H (1978) An analysis of conditions allowingCorynebacterium parvum to cause either augmentation or inhibition of natural killer cell activity against tumor cells in mice. Int J Cancer 21:444–452

  14. 14.

    Peters LJ, McBride WH, Mason KA, Milas L (1978) A role for T-lymphocytes in tumor inhibition and enhancement caused by systemic administration ofCorynebacterium parvum. J Reticuloendothel Soc 24:9–18

  15. 15.

    Savary CA, Lotzora E (1978) Suppression of natural killer cell cytotoxicity by splenocytes fromCorynebacterium parvum-injected, bone marrow-tolerant, and infant mice. J Immunol 120:239–243

  16. 16.

    Scott MT (1972) Biological effects of the adjuvantCorynebacterium parvum. I. Inhibition of PHA, mixed lymphocyte and GVH reactivity. Cell Immunol 5:459

  17. 17.

    Scott MT (1974)Corynebacterium parvum as an immunotherapeutic anti-cancer agent. Semin Oncol 1:367–378

  18. 18.

    Scott MT (1975) Potentiation of the tumor-specific immune response byCorynebacterium parvum. J Natl Cancer Inst 55:65–72

  19. 19.

    Shaeffer J, El-Mahdi A, Constable WC (1975) An experimental model for the treatment of pulmonary metastases. Eur J Cancer 11:523–525

  20. 20.

    Tuttle RL, North RJ (1976) Mechanisms of anti-tumor action ofCorynebacterium parvum: Replicating short-lived T cells as the mediators of potentiated tumor-specific immunity. J Reticuloendothel Soc 20:209–216

  21. 21.

    Zar JH (1974) Biostatistical analysis. Prentice-Hall, Englewood Cliffs, NJ, pp 163–176

  22. 22.

    Zwilling BS, Davis GW (1980) Effect of bacillus Calmette-Guerin on the development of primary lung cancer in Syrian golden hamsters. Cancer Res 40:3455–3458

Download references

Author information

Correspondence to T. I. Mandybur.

Additional information

Supported in part by National Cancer Institute Contract N01-C7-3307 and PHS General Research Support Grant to the University of Cincinnati, College of Medicine

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bash, J.A., Mandybur, T.I. & Ritschel, W.A. The effect of treatment withCorynebacterium parvum on the development and growth of experimental hematogenic metastases of schwannoma in the rat. Acta Neuropathol 68, 22–26 (1985).

Download citation


  • Public Health
  • Tumor Cell
  • Metastatic Tumor
  • Survival Time
  • Untreated Control